MENU
LABD
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

Direxion Daily S&P Biotech Bear 3X ETF (LABD) (LABD) Ownership - Who owns Direxion Daily S&P Biotech Bear 3X ETF (LABD)?

The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index... Show more

Category: #Trading
A.I.Advisor
Nov 20, 2026

What Is Direxion Daily S&P Biotech Bear 3X ETF (LABD)? ETF Overview, Holdings and Investment Strategy

Key Takeaways

  • LABD is a leveraged inverse exchange-traded fund (ETF) that seeks to deliver three times (3X) the opposite of the daily performance of the S&P Biotechnology Select Industry Index.
  • The fund is issued by Direxion and was launched on May 28, 2015; it is managed by Rafferty Asset Management, LLC.
  • LABD is designed for short-term, tactical traders, not long-term buy-and-hold investors, because its leverage resets daily.
  • The fund is non-diversified and gains exposure primarily through derivatives such as swaps, futures, and short positions rather than by directly owning biotech stocks.
  • Its bull counterpart is the Direxion Daily S&P Biotech Bull 3X ETF (LABU).

Introduction

LABD, officially the Direxion Daily S&P Biotech Bear 3X ETF, is a specialized exchange-traded fund built for traders who want aggressive, short-term "bearish" exposure to the U.S. biotechnology sector. Rather than investing in biotech companies to benefit from their success, LABD is engineered to rise when biotechnology stocks fall—and to do so at three times the magnitude of the daily move.

This makes LABD very different from a conventional ETF. It is a trading instrument, not a long-term portfolio building block. Investors follow it for its leverage, its inverse exposure, and its role in hedging or speculating on short-term moves in one of the stock market's most volatile sectors.

ETF Overview and Investment Strategy

LABD seeks daily investment results, before fees and expenses, of 300% of the inverse (the opposite) of the daily performance of the S&P Biotechnology Select Industry Index. In practical terms, if that index declines 1% in a single trading day, the fund aims to gain roughly 3%; if the index rises 1%, the fund aims to lose roughly 3%.

The underlying index is a modified equal-weighted benchmark designed to measure the performance of the biotechnology sub-industry, as classified under the Global Industry Classification Standard (GICS). Because it is equal-weighted rather than market-cap-weighted, the index gives proportionally more weight to smaller and mid-sized biotech companies than a cap-weighted benchmark would, which contributes to its historically higher volatility.

LABD is a passively managed fund that pursues its leveraged inverse objective through derivatives. Under normal circumstances, the fund invests at least 80% of its net assets in financial instruments—including swap agreements, futures contracts, and short positions—that, in combination, provide 3X daily inverse exposure to the index. As a result, its actual portfolio holdings consist mainly of cash, U.S. Treasury instruments, and money-market funds used as collateral, alongside the swap and short positions that generate the inverse returns. Reported holdings commonly include institutional cash-management and Treasury funds from firms such as Goldman Sachs and BNY Mellon (Dreyfus).

The fund is issued by Direxion, a firm known for leveraged and inverse ETFs, and is managed by Rafferty Asset Management, LLC. LABD carries an expense ratio of roughly 1% (approximately 0.95% to 1.07%, depending on the reporting period), which is typical for leveraged products but higher than plain-vanilla index ETFs. It is non-diversified, meaning it can concentrate its positions more heavily than a diversified fund.

Why Investors Follow LABD

LABD attracts attention primarily because of its leverage and its inverse sector exposure. Biotechnology is a uniquely volatile corner of the market, where individual drug approvals, clinical trial results, and regulatory decisions can move entire indices sharply in a single session. For traders with a bearish short-term view on biotech, LABD offers a way to amplify that view without shorting individual stocks.

The fund also serves a hedging role. An investor with broad biotechnology holdings might use a small, temporary position in LABD to help offset short-term declines. Its heavily traded nature and its pairing with the bullish LABU give traders a readily available way to express views in both directions. The same underlying index is tracked by well-known unleveraged funds such as the SPDR S&P Biotech ETF (XBI), which some traders reference for context on the sector's broader market position and portfolio holdings.

Risks and Important Considerations

LABD is among the riskier products available to individual investors, and its key risks stem directly from its design:

  • Daily reset and compounding risk: The fund's 3X inverse objective applies to a single day only. Because leverage resets each trading day, returns over periods longer than one day can diverge significantly from three times the inverse of the index's cumulative return, especially in choppy, sideways markets.
  • Volatility: Leveraged inverse products can experience large, rapid losses. Adverse moves are magnified to the same degree as favorable ones.
  • Derivatives and counterparty risk: LABD relies on swaps and other derivatives to achieve its exposure, which introduces counterparty and financing considerations not present in funds that own stocks directly.
  • Sector concentration: The fund is entirely focused on biotechnology, so it is highly sensitive to industry-specific events such as drug approvals, patent litigation, regulatory changes, and funding conditions for early-stage companies.
  • Costs: The roughly 1% expense ratio, combined with the costs of daily rebalancing and leverage, can erode returns over time.

Direxion itself cautions that leveraged and inverse ETFs are not suitable for all investors and should generally be used only by those who understand leverage risk and actively manage their positions.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies—including leveraged and inverse products like LABD. Explore the AI Screener to see how it can help refine your research workflow.

Conclusion

LABD occupies a distinct niche in the ETF landscape. It offers traders a liquid, leveraged way to bet against the daily direction of U.S. biotechnology stocks, a sector known for sharp swings. Its value lies in short-term tactical use—whether for speculation or temporary hedging—rather than as a long-term holding. For investors who understand its daily-reset mechanics and accept its elevated risk, LABD remains a widely used tool for navigating one of the market's most dynamic industries.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Category
Trading--Inverse Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/

Details

Group
Alternative Funds
Category
Trading
Net Assets
68530000.00
Fund Existence
over 11 years
Turnover
N/A
Capitalization
N/A
Yield
9.84
Total Expense Ratio
1.07
Investment Style
N/A
Risk (Beta)
-3.21